Effectiveness of thymectomy in non-thymomatous myasthenia gravis: a systematic review

Abstract

There is continuous debate regarding the effectiveness of thymectomy in the treatment of non-thymomatous myasthenia gravis (MG). This systematic review was undertaken to determine whether thymectomy was effective in non-thymomatous MG. We retrieved articles published between January 1980 and September 2013. Sixteen cohort studies were included. Given the considerable heterogeneity, we used a descriptive method instead of statistical synthesis. The median relative rates (RRs) and their interquartile ranges were used to estimate the magnitude of benefit. Compared to conservatively treated MG patients, thymectomized patients had higher survival, clinical remission, pharmacologic remission and improvement rates, and RRs were 1.07 (1.01–1.17), 1.83 (0.82–2.99), 1.55 (1.22–1.95) and 1 (1.00–1.09), respectively. Subgroup analyses showed that patients with moderate to severe generalized MG benefited more from thymectomy, with RRs of survival and pharmacologic remission increasing to 1.35 (1.24–1.49) and 2.68 (1.73–4.17), respectively. These results suggested that thymectomy might be an effective procedure in non-thymomatous MG patients. The patients with moderate to severe generalized MG might benefit more. Taking into account the poor methodological quality of present studies, more well-designed prospective randomized controlled trials (RCTs) are still required to reach unequivocal conclusion.

Keywords

myasthenia gravis / thymectomy / systematic review

References

[1] ZeldowiczLR, SaxtonGD. Myasthenia gravis: comparative evaluation of medical and surgical treatment. Can Med Assoc J, 1969, 101(10): 88-93 PMCID: 1946533 PMID: 5348881

[2] EmerykB, StrugalskaMH. Evaluation of results of thymectomy in myasthenia gravis. J Neurol, 1976, 211(2): 155-168 PMID: 55471

[3] GronsethGS, BarohnRJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 2000, 55(1): 7-15 PMID: 10891896

[4] OosterhuisHJ. Observations of the natural history of myasthenia gravis and the effect of thymectomy. Ann N Y Acad Sci, 1981, 377: 678-690 PMID: 6951492

[5] ScaddingGK, HavardCW, LangeMJ, et al. . The long term experience of thymectomy for myasthenia gravis. J Neurol Neurosurg Psychiatry, 1985, 48(5): 401-406 PMCID: 1028325 PMID: 3998750

[6] WarmoltsJR, EngelWK. Benefit from alternate-day prednisone in myasthenia gravis. N Engl J Med, 1972, 286(1): 17-20 PMID: 4331158

[7] GrobD, BrunnerNG, NambaT. The natural course of myasthenia gravis and effect of therapeutic measures. Ann N Y Acad Sci, 1981, 377: 652-669 PMID: 6951490

[8] GrobD, ArsuraEL, BrunnerNG, et al. . The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci, 1987, 505: 472-499 PMID: 3318620

[9] ChristensenPB, JensenTS, TsiropoulosI, et al. . Mortality and survival in myasthenia gravis: a Danish population based study. J Neurol Neurosurg Psychiatry, 1998, 64(1): 78-83 PMCID: 2169901 PMID: 9436732

[10] MantegazzaR, BeghiE, PareysonD, et al. . A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy. J Neurol, 1990, 237(6): 339-344 PMID: 2277266

[11] BeghiE, AntozziC, BatocchiAP, et al. . Prognosis of myasthenia gravis: a multicenter follow-up study of 844 patients. J Neurol Sci, 1991, 106(2): 213-220 PMID: 1802969

[12] JaretzkiA, BarohnRJ, ErnstoffRM, et al. . Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg, 2000, 70(1): 327-334 PMID: 10921745

[13] DownsSH, BlackN. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health, 1998, 52(6): 377-384 PMCID: 1756728 PMID: 9764259

[14] Cochrane Handbook for Systematic Reviews of Interventions Version 4. 2.6 [updated September 2006]: The Cochrane Collaboration; 2006. Available from: www.cochrane.org/sites/default/files/uploads/Handbook4.2.6Sep2006.pdf

[15] MantegazzaR, BaggiF, AntozziC, et al. . Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann N Y Acad Sci, 2003, 998: 413-423 PMID: 14592909

[16] CosiV, RomaniA, LombardiM, et al. . Prognosis of myasthenia gravis: a retrospective study of 380 patients. J Neurol, 1997, 244(9): 548-555 PMID: 9352451

[17] ValliG, JannS, PremoselliS, et al. . Myasthenia gravis treatment: twelve years experience on 110 patients. Ital J Neurol Sci, 1987, 8(6): 593-601 PMID: 3429218

[18] WuWX, WangN. Thymectomy for myasthenia gravis patients and related factors of efficacy, 2011

[19] BachmannK, BurkhardtD, SchreiterI, et al. . Thymectomy is more effective than conservative treatment for myasthenia gravis regarding outcome and clinical improvement. Surgery, 2009, 145(4): 392-398 PMID: 19303987

[20] WerneckLC, CunhaFM, ScolaRH. Myasthenia gravis: a retrospective study comparing thymectomy to conservative treatment. Acta Neurol Scand, 2000, 101(1): 41-46 PMID: 10660151

[21] PapatestasAE, GenkinsG, KornfeldP, et al. . Effects of thymectomy in myasthenia gravis. Ann Surg, 1987, 206(1): 79-88 PMCID: 1492935 PMID: 3606235

[22] PasnoorM, WolfeGI, NationsS, et al. . Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle Nerve, 2010, 41(3): 370-374 PMID: 19882635

[23] Al-MoallemMA, AlkaliNH, HakamiMA, et al. . Myasthenia gravis: presentation and outcome in 104 patients managed in a single institution. Ann Saudi Med, 2008, 28(5): 341-345 PMID: 18779641

[24] TsinzerlingN, LefvertAK, MatellG, et al. . Myasthenia gravis: a long term follow-up study of Swedish patients with specific reference to thymic histology. J Neurol Neurosurg Psychiatry, 2007, 78(10): 1109-1112 PMCID: 2117543 PMID: 17353257

[25] KawaguchiN, KuwabaraS, NemotoY, et al. . Effects of thymectomy on late-onset myasthenia gravis without thymoma. Clin Neurol Neurosurg, 2007, 109(10): 858-861 PMID: 17904281

[26] EvoliA, TonaliPA, PaduaL, et al. . Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain, 2003, 126Pt10: 2304-2311

[27] RobertsonNP, DeansJ, CompstonDA. Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England. J Neurol Neurosurg Psychiatry, 1998, 65(4): 492-496 PMCID: 2170309 PMID: 9771771

[28] BeekmanR, KuksJB, OosterhuisHJ. Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients. J Neurol, 1997, 244(2): 112-118 PMID: 9120493

[29] SetoM, MotomuraM, TakeoG, et al. . Treatment of myasthenia gravis: a comparison of the natural course and current therapies. Tohoku J Exp Med, 1993, 169(1): 77-86 PMID: 8211972

[30] DonaldsonDH, AnsherM, HoranS, et al. . The relationship of age to outcome in myasthenia gravis. Neurology, 1990, 40(5): 786-790 PMID: 2330105

[31] GuillermoGR, Tellez-ZentenoJF, Weder-CisnerosN, et al. . Response of thymectomy: clinical and pathological characteristics among seronegative and seropositive myasthenia gravis patients. Acta Neurol Scand, 2004, 109(3): 217-221 PMID: 14763961

[32] RomiF, AarliJA, GilhusNE. Seronegative myasthenia gravis: disease severity and prognosis. Eur J Neurol, 2005, 12(6): 413-418 PMID: 15885043

[33] SandersDB, El-SalemK, MasseyJM, et al. . Clinical aspects of MuSK antibody positive seronegative MG. Neurology, 2003, 60(12): 1978-1980 PMID: 12821744

[34] KasJ, KissD, SimonV, et al. . Decade-long experience with surgical therapy of myasthenia gravis: early complications of 324 transsternal thymectomies. Ann Thorac Surg, 2001, 72(5): 1691-1697 PMID: 11722066

[35] MachensA, BuschC, EmskotterT, et al. . Morbidity after transsternal thymectomy for myasthenia gravis: a changing perspective?. Thorac Cardiovasc Surg, 1998, 46(1): 37-40 PMID: 9554047